Eli Lilly and Company (NYSE:LLY) Trading 4.5% Higher - Here's Why

Key Points

• Eli Lilly shares rose 4.5% to about $1,280.62 in heavy trading, following strong quarterly results that beat earnings and revenue estimates. Revenue increased 47.7% year over year, supported by the company’s GLP-1 obesity and diabetes portfolio.
• Lilly’s GLP-1 business is reportedly outperforming Novo Nordisk, while clinical progress and partnerships are expanding its pipeline into oral obesity treatments, neuroscience, Alzheimer’s disease and pain therapies.
• Analysts remain broadly positive, with a consensus “Moderate Buy” rating, but investors face risks from intense obesity-drug competition and Lilly’s premium valuation. Recent insider sales occurred under pre-arranged Rule 10b5-1 plans, reducing their bearish significance.

Eli Lilly and Company (NYSE:LLY - Get Free Report) shares shot up 4.5% during trading on Wednesday . The stock traded as high as $1,292.65 and last traded at $1,280.6160. Approximately 4,402,831 shares changed hands during mid-day trading, an increase of 41% from the average session volume of 3,111,745 shares. The stock had previously closed at $1,225.73.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: GLP-1 portfolio is outperforming Novo Nordisk. Lilly’s Q2 obesity and diabetes portfolio reportedly outpaced rival Novo Nordisk’s performance. Investors are also watching Lilly’s oral obesity treatments as it seeks to close or reverse Novo’s early lead in the weight-loss pill market. LLY’s Q2 GLP-1 Portfolio Compared With NVO’s
• Positive Sentiment: Pipeline activity is broadening beyond obesity. Lilly announced or advanced drug-development agreements involving neuroscience and ion-channel programs, including a collaboration with OmniAb and a transaction with AlzeCure that included a $10 million upfront payment. These deals strengthen Lilly’s access to potential Alzheimer’s, pain and other central-nervous-system therapies. Lilly Expands Neuroscience Reach With New Drug Deals
• Positive Sentiment: Key clinical programs are advancing. Updates on lepodisiran, LY4086940 and the oral-candidate formulation LY4065967 indicate continued progress in Lilly’s pipeline. Investors are particularly focused on retatrutide and other next-generation obesity and diabetes treatments as potential future growth drivers. Lilly Advances Oral Pipeline
• Neutral Sentiment: Analysts remain broadly constructive. Lilly screens favorably for long-term growth, with a consensus “Moderate Buy” rating and several price-target increases. However, commentary also emphasizes that much of the expected obesity-drug growth may already be reflected in the valuation. Eli Lilly, Novo Nordisk and Merck: Buy, Sell or Hold?
• Negative Sentiment: Competition and valuation are the main risks. Novo Nordisk remains a significant oral-obesity competitor, while Pfizer is developing a potential monthly obesity treatment that could eventually challenge leading GLP-1 drugs. Lilly’s premium earnings multiple increases sensitivity to clinical, regulatory or commercial setbacks. Pfizer’s Obesity Push
• Negative Sentiment: Insider selling is a minor headwind. EVP Patrik Jonsson sold 6,500 shares for approximately $7.6 million, though the transaction was executed under a pre-arranged Rule 10b5-1 plan, limiting its bearish significance. SEC Insider Transaction Filing

Analyst Ratings Changes

Several research analysts have recently issued reports on LLY shares. Royal Bank Of Canada increased their price target on Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the stock an "outperform" rating in a research note on Wednesday, July 8th. Wells Fargo & Company upped their price objective on shares of Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the stock an "overweight" rating in a report on Thursday, August 6th. Cantor Fitzgerald increased their target price on shares of Eli Lilly and Company from $1,350.00 to $1,410.00 and gave the company an "overweight" rating in a research report on Thursday, August 6th. Morgan Stanley reissued an "overweight" rating and set a $1,419.00 target price on shares of Eli Lilly and Company in a research note on Thursday, August 6th. Finally, Bank of America upped their price target on shares of Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the stock a "buy" rating in a research note on Friday, July 10th. One analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $1,292.18.

Eli Lilly and Company Stock Performance

The company has a current ratio of 1.35, a quick ratio of 1.00 and a debt-to-equity ratio of 1.41. The company's 50-day moving average price is $1,173.20 and its two-hundred day moving average price is $1,055.15. The company has a market cap of $1.21 trillion, a P/E ratio of 42.97, a price-to-earnings-growth ratio of 1.39 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, topping analysts' consensus estimates of $6.40 by $1.98. The business had revenue of $22.97 billion for the quarter, compared to the consensus estimate of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The business's revenue for the quarter was up 47.7% on a year-over-year basis. During the same period in the previous year, the firm earned $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, equities analysts forecast that Eli Lilly and Company will post 36.35 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 0.5%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company's dividend payout ratio is currently 23.22%.

Insiders Place Their Bets

In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of the company's stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the completion of the sale, the executive vice president directly owned 11,875 shares of the company's stock, valued at approximately $14,131,250. This represents a 29.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald A. Zakrowski sold 2,000 shares of the firm's stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the completion of the transaction, the chief accounting officer owned 1,526 shares of the company's stock, valued at approximately $1,808,325.26. The trade was a 56.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 13,500 shares of company stock worth $15,958,170. Company insiders own 0.14% of the company's stock.

Hedge Funds Weigh In On Eli Lilly and Company

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Field & Main Bank purchased a new stake in shares of Eli Lilly and Company in the second quarter valued at $9,426,000. Prosperitas Financial LLC acquired a new position in Eli Lilly and Company during the second quarter valued at $5,659,000. Goodwin Investment Advisory purchased a new stake in Eli Lilly and Company in the 2nd quarter worth about $299,000. Lombard Odier Asset Management Europe Ltd acquired a new stake in Eli Lilly and Company during the 2nd quarter worth about $23,148,000. Finally, Archer Investment Corp boosted its position in Eli Lilly and Company by 10.6% during the 2nd quarter. Archer Investment Corp now owns 8,262 shares of the company's stock worth $9,909,000 after acquiring an additional 795 shares during the period. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source